Company news
Verrica Pharmaceuticals Inc. news in 2021
Verrica Pharmaceuticals Inc.'s news releases, calls and decks from 2021, newest first.
Verrica Pharmaceuticals Announces Acceptance by FDA of NDA Resubmission for VP-102 for the Treatment of Molluscum Contagiosum
December 14, 2021
Verrica Pharmaceuticals Announces Resubmission of New Drug Application for VP-102 for the Treatment of Molluscum Contagiosum
November 28, 2021
Verrica Pharmaceuticals Announces FDA Acceptance of its IND Application for LTX-315, a Potential First-in-Class Oncolytic Peptide-Based Immunotherapy, for the Treatment of Basal Cell Carcinoma
November 17, 2021
Verrica Pharmaceuticals Reports Third Quarter 2021 Financial Results
November 11, 2021
Verrica Pharmaceuticals Receives Complete Response Letter from the FDA identifying deficiencies at a facility of a Contract Manufacturer for its New Drug Application for VP-102 for the Treatment of Molluscum Contagiosum
September 19, 2021
Verrica Pharmaceuticals Reports Second Quarter 2021 Financial Results
August 9, 2021
Verrica Pharmaceuticals Announces Appointment of Terry Kohler as Chief Financial Officer
July 8, 2021
Verrica Pharmaceuticals Announces Extension of FDA Review Period of its NDA for VP-102 for the Treatment of Molluscum Contagiosum
May 27, 2021
Verrica Pharmaceuticals Announces Participation in the 2021 RBC Capital Markets Global Healthcare Conference
May 11, 2021
Verrica Pharmaceuticals Reports First Quarter 2021 Financial Results
May 6, 2021
Verrica Pharmaceuticals Announces Participation in the 20th Annual Needham Virtual Healthcare Conference
April 5, 2021
Verrica Announces Election of Gary Goldenberg, MD, Verrica’s Chief Medical Officer, to Membership in the American Dermatological Association
March 28, 2021
Verrica Pharmaceuticals Announces Exclusive Licensing Agreement With Torii Pharmaceutical Co., Ltd. To Develop and Commercialize VP-102 For Molluscum and Common Warts in Japan
March 16, 2021
Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2020 Financial Results
March 3, 2021
Verrica Pharmaceuticals Announces Participation in the H.C. Wainwright Annual Global Life Sciences Conference
March 2, 2021
Verrica Pharmaceuticals Announces FDA Filing Acceptance of Resubmitted New Drug Application for VP-102 for the Treatment of Molluscum Contagiosum
February 16, 2021
Decks in 2021
- Investor Presentation (November 2021)
Investor deck · 60 slides · Nov 29, 2021
- Investor Presentation (September 2021)
Investor deck · 60 slides · Sep 29, 2021
- Investor Presentation (January 2021)
Investor deck · 58 slides · Jan 6, 2021